Meeting News CoverageVideo

ABT-493, ABT-530 produce high SVR rates in HCV genotype 3

BARCELONA — In this exclusive video interview at International Liver Congress, Paul Y. Kwo, MD, professor of medicine and director of liver transplantation at Indiana University, and HCV Next Editorial Board member, discusses results from the two SURVEYOR studies investigating the safety and efficacy of pangenotypic agents ABT-493 and ABT-530 in patients with hepatitis C virus genotype 3 infection with and without cirrhosis.

“We are clearly in need of different strategies for these individuals so the genotype 3 population can get the same benefits as the other [genotype patients],” Kwo told HCV Next.

In the first study, 29 treatment-naive patients with HCV genotype 3 without cirrhosis were given a once-daily regimen of 300 mg of ABT-493 (AbbVie) plus 120 mg of ABT-530 (AbbVie) for 8 weeks. Of these, 97% achieved sustained virologic response at 4 weeks (n = 28).

In the second study, 48 patients with HCV genotype 3 with cirrhosis were randomized to a once-daily regimen of 300 mg of ABT-493 and 120 mg of ABT-530 with or without 800 mg of ribavirin for 12 weeks. Of these, 100% achieved SVR following 12 weeks of treatment with and without ribavirin.

“I think [the combination] will be a welcome addition … for hepatitis C,” Kwo said.

Reference:

Kwo PY, et al. Abstract LB01. Presented at International Liver Congress. April 13-17, 2016; Barcelona.

Muir AJ, et al. Abstract PS098. Presented at International Liver Congress. April 13-17, 2016; Barcelona.

Disclosure: Kwo reports multiple financial relationships with AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

BARCELONA — In this exclusive video interview at International Liver Congress, Paul Y. Kwo, MD, professor of medicine and director of liver transplantation at Indiana University, and HCV Next Editorial Board member, discusses results from the two SURVEYOR studies investigating the safety and efficacy of pangenotypic agents ABT-493 and ABT-530 in patients with hepatitis C virus genotype 3 infection with and without cirrhosis.

“We are clearly in need of different strategies for these individuals so the genotype 3 population can get the same benefits as the other [genotype patients],” Kwo told HCV Next.

In the first study, 29 treatment-naive patients with HCV genotype 3 without cirrhosis were given a once-daily regimen of 300 mg of ABT-493 (AbbVie) plus 120 mg of ABT-530 (AbbVie) for 8 weeks. Of these, 97% achieved sustained virologic response at 4 weeks (n = 28).

In the second study, 48 patients with HCV genotype 3 with cirrhosis were randomized to a once-daily regimen of 300 mg of ABT-493 and 120 mg of ABT-530 with or without 800 mg of ribavirin for 12 weeks. Of these, 100% achieved SVR following 12 weeks of treatment with and without ribavirin.

“I think [the combination] will be a welcome addition … for hepatitis C,” Kwo said.

Reference:

Kwo PY, et al. Abstract LB01. Presented at International Liver Congress. April 13-17, 2016; Barcelona.

Muir AJ, et al. Abstract PS098. Presented at International Liver Congress. April 13-17, 2016; Barcelona.

Disclosure: Kwo reports multiple financial relationships with AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Merck.

    See more from International Liver Congress